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ESTUDIO PILOTO SOBRE EL EFECTO DE LA
SUPLEMENTACIÓN CON ÁCIDO FÓLICO
EN LA MEJOR DE LOS NIVELES DE
HOMOCISTEÍNA, FUNCIÓN COGNITIVA
Y ESTADO DEPRESIVO EN TRASTORNOS
DE LA CONDUCTA ALIMENTARIA
Resumen
Introducción y objetivo: Diferentes autores han repor-
tado una baja ingesta de ácido fólico en pacientes con
Trastornos de la Conducta Alimentaria (TCA). Esta vita-
mina desempeña un papel esencial en las reacciones de
síntesis de neurotransmisores y elementos estructurales
de las neuronas y, por lo tanto, su deficiencia se ha aso-
ciado con la presencia de diferentes trastornos relaciona-
dos con la función mental. El objetivo de este estudio fue
determinar el efecto de la suplementación con ácido fólico
sobre los niveles de homocisteína y sobre marcadores de
función cognitiva y depresión en un grupo de pacientes
con TCA con baja ingesta de ácido fólico.
Sujetos y métodos: Estudio clínico randomizado y pros-
pectivo en el que se incluyeron 24 pacientes asignados a
dos grupos de tratamiento durante un período de 6
meses: grupo suplementado (SG) (10 mg/día de ácido
fólico [ACFOL®]) y grupo placebo (PG). Ambos grupos
mantuvieron su tratamiento médico, dietético y psicoló-
gico. Al inicio del estudio y tras la intervención se evalua-
ron parámetros antropométricos, dietéticos y bioquími-
cos (homocisteína  plasmática [Hcy], folato sérico y
eritrocitario). Como marcadores de función cognitiva y
depresión se administraron diferentes cuestionarios (Test
de Stroop, Trail Making Test, BDI: Cuestionario de per-
cepción de función cognitiva).
Resultados: Completaron el estudio 22 pacientes (SG:
12, PG: 10, edad media: 24,2 ± 8,8 años, IMC 18,9 ± 3,5
kg/m2). El grupo SG incrementó de forma significativa sus
niveles de folato sérico y eritrocitario y redujo el de homo-
cisteína (9,4 ± 2,4 μmol/l vs. 7,5 ± 1,7 μmol/l, P < 0,01). Ade-
más, el grupo SG también mejoró significativamente las
puntuaciones de los test de función cognitiva y depresión.
En el grupo PG, en cambio, no se observaron cambios sig-
nificativos en ninguna de las variables evaluadas.  
Conclusiones: Los resultados obtenidos demuestran
que la suplementación con ácido fólico podría emplearse
como una herramienta más dentro del complejo y multi-
disciplinario tratamiento que requieren estos pacientes.
(Nutr Hosp. 2013;28:807-815)
DOI:10.3305/nh.2013.28.3.6335
Palabras clave: Folato. Función cognitiva. Trastorno ali-
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Abstract
Background & aims: Several authors have reported
low folate intake in patients with eating disorders (ED).
This vitamin plays an essential role in synthesis reactions
for neurotransmitters and structural elements of
neurons, and therefore its deficiency has been associated
with the presence of different disorders linked to mental
function. The aim of this study was to determine the effect
of folic acid supplementation on homocysteine levels and
the cognitive and depressive status of a group of patients
with eating disorders with low folate intake. 
Subjects/methods: The study was designed as a
randomised, prospective clinical trial, which included 24
participants assigned to two treatment groups for six
months: supplemented group (SG) (10 mg/day of folic
acid [ACFOL®]) and a placebo group (PG). Both groups
maintained their medical, dietary and psychological
treatment. At baseline and end of the intervention,
anthropometric, dietary and biochemical parameters
(plasma homocysteine [Hcy], serum and red blood cell
folate) were recorded. Cognitive and depressive status
questionnaires were administered (Stroop Test, Trail
Making Test and Beck Depression Inventory). 
Results: Twenty-two patients completed the study (SG:
12, PG: 10, mean age: 24.2 ± 8.8 years, BMI 18.9 ± 3.5
kg/m2). The SG significantly increased their serum and
red blood cell folate levels and lowered Hcy levels (9.4 ±
2.4 μmol/l vs. 7.5 ± 1.7 μmol/l, P < 0.01). The SG also
significantly improved most of their test scores for cogni-
tive and depressive status. The PG showed no significant
changes in any of the evaluated variables.  
Conclusions: The results show that folic acid supple-
mentation may be used as another tool within the
comprehensive and multidisciplinary treatment applied
to patients with ED. 
(Nutr Hosp. 2013;28:807-815)
DOI:10.3305/nh.2013.28.3.6335
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Abbreviations
ED: Eating Disorders.
RA: Restrictive Anorexia Nervosa.
EDNOS: Eating Disorder Not Otherwise Specified.
PG: Placebo group.
SG: Supplemented group.
Hcy: Homocysteine.
ST: Stroop test.
TMT: Trail Making Test.
BDI: Beck Depression Inventory.
Introduction
Folate deficiency is a common nutritional problem
in many populations groups. This deficiency may be
due to absorption disorders, genetic factors, drug inter-
actions and inadequate diet.1
Several authors have reported low folate intake in
patients with eating disorders (ED).2,3 The severe food
restriction of that patients, especially those with
Restrictive Anorexia Nervosa (RAN), causes them to
have diets deficient in both energy and micronutrients,
among them folate. 
Folate is the generic term for the various chemical
forms of folic acid that can only be synthesised by
plants and microorganisms, thus requiring it to be
ingested through diet.4,5 This vitamin plays an essential
role in synthesis reactions for neurotransmitters and
structural elements of neurons,6 and therefore its defi-
ciency has been associated with the presence of
different disorders linked to mental function such as
depression6-8 and cognitive function impairment.9 The
effect of folic acid supplementation has been studied as
a tool for improving these disorders, with conflicting
results.10-13
Some authors have identified the presence of increased
homocysteine levels in eating disorders patients,14-17 and
attempts have been made to find some association
between this and the high rates of depression18,19 and cogni-
tive function impairment recorded in these patients.20,21 It is
still not known what causes this increase in homocysteine
levels, whether the levels return to normal after the nutri-
tional state is normalised and what strategies must be
employed to carry out this normalisation.22
The aim of this study was to determine the effect of
folic acid supplementation on homocysteine levels in
an ED group of patients. The secondary objectives
were to evaluate the outcome on cognitive and depres-
sive status after the intervention.
Subject/methods
Study participants
This study was designed as a prospective, rando-
mised, double-blind, parallel-placebo clinical study,
developed by the Nutrition Department of “La Paz
University Hospital” in the period between January
2008-June 2010. Twenty-four males and females
diagnosed with eating disorders (RAN: Restrictive
Anorexia Nervosa and EDNOS: Eating Disorder Not
Otherwise Specified) through clinical interviews with
the Psychiatry Department and measured for low
folate intake, based on the recommended daily intake
in terms of age,23 were included consecutively. Exclu-
sion criteria were: hypersensitivity to folic acid or
anemia due to lack of B12, patients who routinely
used drugs that interfere with folic acid absorption
(analgesics, anticonvulsants, hydantoin, carbamaze-
pine, antacids, antibiotics, cholestyramine, methotre-
xate, pyrimethamine, triamterene, trimethoprim and
sulphonamides) and patients taking vitamin and
mineral supplements.
All participants or their relatives, in the case of
minors, signed an informed consent for participation.
The study was approved by the Ethics Committee of the
La Paz University Hospital and conformed to the ethical
standards of the Declaration of Helsinki. Registered
under ClinicalTrials.gov Identifier no. NCT01493674.
Interventions
Patients were randomly assigned to two treatment
groups. The treatment groups consisted of a supple-
mented group (SG) using two 5-mg tablets of folic acid
(ACFOL®), and a placebo group (PG) using two tablets
that were identical to those of SG, but composed of
crystalline cellulose, lactose and food colouring.
Groups were treated for six months. Patients continued
the standard medical, dietary and psychological treat-
ment established for these patients within the Nutrition
Department.
Methods
The following data were collected at baseline and at
the end of the study: 
– Anthropometric parameters: height (SECA
stadiometer [range: 80 cm to 200 cm]) and weight
(TANITA BC-420MA, Biologica Tecnologia
Medica S.L, Barcelona, Spain) were measured.
BMI was calculated using the equation: weight
(kg)/[height (m)]2.
– Dietary parameters: all food and beverages
consumed were recorded using a food frequency
questionnaire and a “3-day food and drink
record”, validated for Spanish population.24 The
food's energy and nutritional content was then
calculated using nutrition software (DietSource®
3.0, Novartis, Spain). The values obtained were
compared to the recommended values to deter-
mine the diets' nutritional adequacy.23,30
808 Viviana Loria-Kohen et al.Nutr Hosp. 2013;28(3):807-815
34. A PILOT_01. Interacción  16/04/13  13:49  Página 808
– Blood variables: hematology determinations were
performed using an ABX Pentra 120 autoanalyser
(Horiba). Serum and red blood cell folate and
vitamin B12 levels were determined by a Modular
Analytics E 170 autoanalyser (Roche). Plasma
homocysteine was quantified by nephelometry
using a Prospec autoanalyser (Siemens). The
following reference values were used for the diag-
nosis of folate deficiency: serum folate < 3 ng/ml,
red blood cell folate < 140 ng/ml, Hcy > 8 μmol/l
and vitamin B12 < 258 pmol/l.25
– Depressive and cognitive status:
– • Depressive symptomatology was assessed
using the Beck Depression Inventory (BDI).26
The BDI is a 21-item self-report scale
measuring the depression severity (range 0-63).
Depression absence is defined as a total score
below 12, moderate depressive symptoms as a
score between 12 and 17 and a clinically rele-
vant depression, 18 or above. 
– • Selective attention and executive function was
measured using the Stroop colour-word inter-
ference test.27 The first part of the test (named P)
consists of reading the names of colours printed
in black ink, and measures verbal ability and
attention. In the second part of the test (named
C), participants have to name the colour (blue,
green or red) of a series of printed dashes. In the
third part (named PC), participants have to
name the colour of coloured words printed in
incongruent ink colours instead of reading the
name. Interference (I) is calculated using the
scores from the three test parts and measures the
ability to adapt to changing demands and
suppress habitual responses in favour of
unusual ones [I = PC-(C*P)/(C + P)]. The T
score was determined by crossing the variables
in the score calculation table.27 Normal limits
for T scores ranged from 35 to 65 points. To
assess the various parts of the test, the following
scales were used for Spanish population:28
Stroop scores Test Test Test Interference
card P card C card PC
Adults 16 to 44
years of age 119 79 50 2.71
(mean values)
– • Trail Making Test,29 evaluates visual search
speed, attention, visuospatial sequencing, mental
flexibility and motor function. The test has two
parts: TMT-A (participants have to connect
digits from 1 to 25 in ascending order after they
have performed a similar training task with only
8 digits), and TMT-B [participants have to
connect digits and letters sequentially (1-A, 2-B,
… 13-L)]. The test variable was the time in
seconds needed to correctly complete the task. In
accordance with Frieling et al. (2005), TMT
values were scored as paired or unpaired (Cut-
off: TMT-A > 40s; TMT-B > 85s).
Prior to completing the cognitive function question-
naires, the patient was checked to make sure they were
not fasting and were getting a regular amount of sleep,
in order to minimise the effects of these factors on the
results.
Other interesting medical parameters were recorded
at baseline: age and time of disease diagnosis.
Statistical analysis
Analysis was performed using the SPSS 9.0
programme (SPSS Inc., Chicago, IL, USA). Contin-
uous variables are shown as mean (standard deviation
[SD]). Qualitative variables are shown as absolute
frequencies and percentages. Due to the sample size,
the Shapiro-Wilk test was used for performing
normality tests. When the distribution of the results
was normal, the Student t test was used to compare the
mean values of the studied variables recorded for the
two treatment groups. The Mann-Whitney U test was
used when the distribution was not normal. Differences
within groups at the beginning and end of the study
were examined using the Student paired t test when the
distribution of the results was normal, and the
Wilcoxon test when it was not. We also calculated
linear correlation coefficients using the Pearson's test
when at least one of the variables was normally distrib-
uted, or the Spearman’s test when both were not
normal. Values of p < 0.05 were considered significant
for all statistical tests.
Results
Twenty-four patients were recruited (SG: 14, PG:
10). Two patients in the SG withdrew from the Nutri-
tion Department's standard treatment, so the data from
their last visit could not be obtained and they were
excluded (PG: 12, PG: 10). No side effects were
reported during treatment.
At the start of the study there were no significant
differences in the values of any of the variables studied
(table I). After assessing folate intake by means of the
food record, we observed that half of the group did not
meet 30% of the recommended daily intake for their
age (400 μg/day).
The total study sample presented baseline serum and
red blood cell folate and vitamin B12 levels within
reference values: 9.7 ± 3.3 ng/ml; 725.6 ± 306.1 ng/ml
and 654.0 ± 309.1 pg/ml, respectively. Mean Hcy
values were 9.4 ± 2.4 µmol/l. The only male included in
the study had 7.8 μmol/l.
In terms of the correlation between Hcy levels and
the specific variables linked to metabolism of this
A pilot study of folid acid
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amino acid (folate, vitamin B12), only an inverse and
weak correlation between homocysteine and vitamin
B12 was found (r = -0.412 P < 0.05).
About cognitive function results at baseline, 8.3% of
participants scored below the mean of the reference in
P, and 33.3% in C and CP test cards for Stroop test
(ST). Some 33.3% scored below the I mean. Only one
patient (4%) had a T score outside normal ranges.27
Regarding TMT, 8.4% scored above the reference cut-
off used in part A and 20.8% in part B.21 About depres-
sion symptoms assessment at baseline, 20.8% scored in
the moderate range of depression and 58.3% scored in
relevant or severe ranges on the BDI.26
After six months of intervention, there were no
significant changes in caloric or macronutrient intake.
In terms of micronutrients, significant differences were
only observed in the total folate intake. The SG had a
greater increase of this nutrient as a result of supple-
mentation (28.0 ± 65.5 vs. 9995.2 ± 58.8 µg/day; P <
0.001). 
Biochemical parameters evolution after the inter-
vention is shown in table II. The SG significantly
increased their serum and red blood cell folate levels
and lowered Hcy levels. There were no significant
changes in vitamin B12 levels in either treatment
group. 
The evolution of scores from the different question-
naires is shown in table III. The SG significantly
lowered the time spent resolving part B of the TMT and
increased the number of words read in the ST test cards
P, C and CP. BDI scores were also significantly lower
(figs. 1, 2). There were no significant changes in any of
the tests assessed for the PG. 
The increase in total folate intake in SG correlated
significantly and inversely with the change in BDI
scores (r = -0.581, P < 0.05), but not with other ques-
tionnaires.
In terms of BMI evolution, the SG significantly
increased their BMI (18.9 ± 3.2 vs. 20.1 ± 2.6 kg/m2; P
< 0.05). PG did not change this parameter (18.8 ± 3.9
vs. 18.6 ± 4.0 kg/m2). Also, the differences between the
variations of the groups were significant (SG: 1.4 ± 1.9
vs. PG: -0.2 ± 1.2 kg/m2; P < 0.05). There were no
significant correlations between BMI changes and in
the questionnaires scores changes or in the Hcy
changes. The coefficients of determination R2 indi-
cated that only a low and insignificant percentage of
the change in the variation of studied variables may be
attributed to the variation in BMI (Stroop P: R2 = 0.004,
P = 0.788; Stroop C: R2 = 0.03, P = 0.806; Stroop PC:
R2 = 0.035, P = 0.406; TMT-A: R2 = 0.079, P = 0.206;
TMT-B: R2 = 0.044, P = 0.347; BDI: R2 = 0.159 P =
0.066; Hcy R2 = 0.009, P = 0.077). 
When studying the relationship between patient age
and time of diagnosis of the disease with the changes at
the end of the intervention, there were no significant
correlations in any of them.
Discussion
After six months of a 10-mg/day folic acid supple-
mentation in EDs patients, there was an improvement
in folate status and a significant reduction in Hcy
levels. Additionally, there were significant and
favourable changes in most cognitive function and
depression test scores. 
At baseline of the study, folate intake of all patients
was deficient (< 67% RDI), and did not achieve 30% of
the recommended daily intakes.30 These values are
similar to previous studies.2,31
Folate is involved in various biological functions
necessary for achieving a healthy state. Some studies
suggest that deficient folate status is associated with
high levels of Hcy.9,32 Hcy levels above 10 µmol/l are
linked to a poor cognitive state and depression.33
The median for Hcy in our groups [9.6 µmol/l
(range: 5.2 to 14.4)] was greater than reference values
for the Spanish population [7.79 µmol/l (range: 4.3 to
17.7)].32 Some 66% of the sample had baseline Hcy
levels greater than the reference value considered for
indicating folate deficiency (> 8 µmol/l).1 Moreover, it
has been observed that 42% of all the patients had base-
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Table I
Socio-sanitary characteristics of the study group.
Data expressed as mean (SD) and percentage
Supplemented Placebo
group group
n = 14 n = 10
Age (years) 22.3 (7.6) 26.7 (10.0)
Evolution time (years) 3.5 (7.4) 7.1 (8.9)
Diagnosis (DSM IV) (%)
RAN 50.0 42.9 
EDNOS 50.0 57.1
Education level (%)
UE 46.2 66.6
SE 23.0 11.2
PE 30.8 22.2
Consumption of psychoactive drugs (%)
Antidepressants 57.1 70.0
Anxiolytics 42.9 30.0
Mood stabilisers 7.0 0.0
Dietary intake
Energy (kcal) 3.96  (1.39) 4.75 (2.32)
Folates (µg/day) 114.5 (51.7) 143.3 (77.2)
% coverage of RDI of folic acid 28.6 (12.9) 35.8 (19.3)
Vitamin B12 2.3 (1.2) 3.1 (2.4)
% coverage of RDI of B12 96.7 (51.1) 130.4 (103.1)
RAN: Restrictive Anorexia Nervosa; EDNOS: Eating Disorder Not Otherwise Speci-
fied; UE: University education (completed or in progress); SE: Secondary education
(completed or in progress); PE: Primary education; RDI: Recommended Dietary
Intake.
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line Hcy levels greater than the value indicative of a
health risk.33
The presence of high Hcy levels has been reported in
ED patients.14-17 However, we should take into account
the significant variability in the data collection and
analysis methods, such as the control markers used,
which must be considered when interpreting and
comparing these data.32,34
Despite ED patients have a high nutritional risk for
some nutrients,3 both groups in our study had normal
blood vitamin B12 and serum and red blood cell folate
levels, an observation found in other studies.14,16
Vitamin B12 deficiency is rare since the ratio of
cobalamin body reserves to its normal daily require-
ments is approximately 1000:1, which makes it diffi-
cult to develop a deficiency in this vitamin based solely
on a deficient diet. Its deficiency is caused more by
congenital errors in metabolism or by gastrointestinal
problems related to surgery, age, etc.1 Previous studies
have not found vitamin B6 deficits in patients with ED,
and Hcy levels were not reduced after supplementing
with this vitamin.15 However, some authors suggest
that conventional criteria for the folate deficiency diag-
nosis may be inadequate to identify individuals who
may benefit from dietary supplements,9 since finding
appropriate levels would not reflect the actual situa-
tion. Therefore, to understand the exclusive effect of
folate on the study variables, we decided to perform
folic acid supplementation and not in combination with
B6 and B12, as was done in many previous studies.10-12
Before carrying out an intervention with folic acid,
vitamin B12 deficiency had to be ruled out since both
nutrients use common metabolic pathways, and
supplementation with folic acid may mask B12 defi-
ciency.9 In our study, folic acid supplementation in the
doses and times used did not cause a significant reduc-
Table II
Evolution of biochemical parameters after intervention. Data expressed as mean (SD)
Pre-intervention Post-intervention Difference
Supplemented Placebo Supplemented Placebo Supplemented Placebo
group group group group group group
n = 14 n = 10 n = 12 n = 10 n = 12 n = 10
Homocysteine (µmol/l) 9.4 (2.4) 10.0 (2.05) 7.5 (1.7) a** 8.0  (1.8) -2.0 (1.8) -1.6 (2.0) 
Serum folate (ng/ml) 9.4 (3.6) 10.2 (3.8) 19.6 (1.3) a*** 10.9 (3.8) 10.6 (3.4) 0.4 (2.0) b***
Red blood cell folate (ng/ml) 634.3 (300.0) 844.4 (285.4) 1,521.7 (167.0) a*** 945.0 (347.0) 919.0 (311.0) 119.1 (101.7)b*** 
Vitamin B12 (pg/ml) 562.6 (209.5) 782.0 (387.0) 580.6 (223.3) 762.8 (468.3) 14.9 (124.6) 34.9 (172.6)
Haematocrit (%) 39.1 (1.8) 39.4 (3.2) 38.8 (2.0) 39.8 (2.0) -0.8 (1.5) 0.1 (38.0)
Haemoglobin (g/dl) 13.0 (0.6) 13.5 (0.9) 13.0 (0.8) 13.4 (0.9) -0.2 (0.7) -0.2 (0.2)
aIntra-group differences after 6 months of intervention. 
bDifferences between groups after 6 months of intervention. 
Level of significance  *P < 0.05, **P < 0.01, ***P < 0.0001.
Table III
Changes in mean scores for cognitive function, depression and perception of cognitive impairments tests after
intervention. Data expressed as mean (SD)
Pre-intervention Post-intervention
Supplemented Placebo Supplemented Placebo
group group group group
n = 14 n = 10 n = 12 n = 10
TMT-A (s) 31.8 (19.0) 26.7 (9.04) 27.5 (11.9) 23.4  (9.3)
TMT-B (s) 78.8 (58.9) 63.8 (39.2) 52.3 (24.0)a* 61.3 (42.1)
P-Stroop (nw) 99.8 (19.5) 104.0 (16.0) 105.6 (21.4)a* 110.1 (18.2)
C-Stroop (nw) 70.6 (16.8) 65.5 (13) 77.1 (17.3)a* 70.0 (16.2)
PC-Stroop (nw) 45.9 (10.8) 44.7 (11.6) 49.2 (11.2)a* 47.6 (14.0)
I-Stroop 5.9 (6.9) 4.7 (7.6) 5.1 (6.9) 5.0 (7)
PT-Stroop 55.5 (7.1) 54.0 (6.2) 55.7 (6.1) 54.9 (6.9)
BDI 22.9 (8.1) 17.3 (12.1) 15.2 (9.9)a* 13.4 (11.8)
s: seconds; nw: number of words; TMT-A: Trail Making Test part A; TMT-B: Trail Making Test part B; P, C and PC: Stroop test sheets; I: interference; TS: T score; BDI:
Beck Depression Inventory.
aIntra-group differences after 6 weeks of intervention. 
Level of significance *P < 0.05.
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*
Fig. 1.—The supplemented
group (SG) significantly in-
creased the number of
words read in the Stroop
Test (ST) test cards P after
the intervention.
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tion in vitamin B12 levels whose baseline values were
within normal ranges.
After the intervention, SG showed significant
changes in various parameters linked to folate status,
increasing both serum and red blood cell folate. More-
over, only SG experienced a drop in Hcy values. Other
interventions with folic acid, mainly on elders, also
achieved improvements in folate nutritional state as
well as significant reductions in Hcy levels.11-13,35
EDs are associated with cognitive function impair-
ment.20,21 Based on studies performed on Alzheimer’s
patients, which associate increased Hcy with cognitive
impairment,36 it is hypothesised that high Hcy levels
may contribute to cognitive impairment in ED patients.
Baseline cognitive status of participants assessed
with the Stroop test showed that almost a third of them
were below the mean scores for the same age Spanish
population.28 However, baseline Hcy levels were not
significantly correlated to test scores. Frieling et al.
(2005) assessed the cognitive function of patients with
ED using this test and obtained scores and percentages
similar to those found at baseline in our study. They
also did not find a relationship between Hcy levels and
Stroop test scores. These results suggest that Hcy
levels may not immediately reflect cognitive function
impairment.
After the intervention, only SG improved their
cognitive state, significantly increasing the number of
words read in the P, C and CP test sheets. The changes
in scores for PG were not significant. 
After the intervention, SG improved their cognitive
state, significantly reducing the time spent in solving
TMT part B. As in the previous test, despite the fact
that a reduction in test times was expected due to repe-
tition of the test, the changes in the times for the PG
were not significant. 
It has been suggested that depression symptoms in
patients with ED occur due to neuroendocrinological
disorders induced by food restriction.19 According to
scores obtained for the BDI, more than three quarters
of all participants achieved scores indicative of depres-
sion. The prevalence rates for depression reported in
ED patients ranged from 35% to 85%, and are greater
in patients with RAN.18,19 Frieling et al. (2008), using
the same test, obtained baseline scores that were equal
to those of our study and found a significant correlation
between baseline Hcy levels and test scores,19 which
was not observed in our study or other recently
performed study.22
After the intervention, SG improved their depressive
state by significantly reducing BDI scores, which was
not observed in PG. Although only 7.1% of the SG
scored in normal ranges at baseline, the percentage
increased to 41.7% after the intervention. The
percentage of those who scored in the severe ranges
also decreased (78.6% to 33.3%). The evolution of the
percentages in the normal range in the PG was from
40% to 60%, and fell 10% for severe cases. We should
note that for this analysis both groups received routine
psychiatric and psychological treatment, which
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explains the positive evolution of PG. In addition, it
was observed that BDI scores changes were signifi-
cantly correlated with total folate intake changes.
Therefore, oral supplementation with folic acid may
prove to be beneficial in the treatment of this type of
disorder in patients with ED.
We have not found previous studies on ED patients
who supplemented with folic acid. However, we can
find extensive literature with conflicting results on the
influence of folate and folic acid supplementation on
cognitive function in individuals with cognitive impair-
ment due to age and dementia. A review by Cochrane
concludes that there was no evidence of benefit from
folic acid supplementation with or without the addition
of B12 compared to placebo in some of the measures of
cognition and mood in healthy individuals with cogni-
tive impairment or dementia. However, in a trial that
recruited healthy elderly people with high Hcy levels,
the administration of folic acid supplements for three
years was associated with a significant benefit in overall
function, memory capacity and information processing
speed. The authors suggest that more studies are neces-
sary in this area.9 It should be noted that most of the
review studies are on elders, which means that some of
the neurological lesions may be irreversible despite
supplementation.
About the anthropometric parameters evolution after
intervention, SG significantly increased their BMI, a
condition not observed in PG. Previous studies have
shown that nutritional rehabilitation (without vitamin
B complex supplementation) may significantly reduce
Hcy levels.14 In contrast, a recent study observed that
after nutritional treatment (not specified by the
authors) there was a significant increase in BMI and yet
Hcy, folate and B12 levels did not change and there
were no changes in most of the cognitive function tests
used.22 In our study, the increase in BMI after the inter-
vention was not associated with improved results in
both Hcy levels and test scores. 
Other determinants of the evolution of cognitive and
depressive status, may include age and time of diag-
nosis of the disease.16 However, in our study there was
no association between them. 
This study is the first clinical trial, to our knowledge,
that used folic acid supplements to assess changes in
cognitive and depressive status in EDs patients. Another
*
Fig. 2.—The supplemented
group (SG) significantly lo-
wered Beck Depression In-
ventory (BDI) scores after
the intervention.
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strength was the exclusive folic acid supplementation,
not in combination with other B vitamins. This allowed
us to isolate the results for this vitamin and to verify the
folic acid supplementation use in participants without
prior deficiencies does not cause negative effects on
vitamin B12 levels. It is also noteworthy that an exten-
sive battery of tests was used to assess the evolution in
cognitive and depression status (Stroop, TMT, and
BDI), since current evidence suggests that Hcy levels
alone cannot report on the clinical repercussion in cogni-
tive and depressive status.
One of the limitations of this study was the small
sample size. Nevertheless, other EDs patients publica-
tions have similar sample sizes. The small size is
consequence of the low prevalence of this disease
coupled with the strict exclusion criteria. The small
sample size precludes a proper analysis by subgroups,
which would have been of great interest. Moreover, the
inclusion of a healthy control group would have been
of significant value for comparing baseline test results
with a reference population. 
Positive evolution of the cognitive and depressive
status observed in SG may contribute to improving
their quality of life and recovery. This fact demon-
strates the scientific importance of this study, since
folic acid supplementation may be used as tool within a
comprehensive and multidisciplinary treatment for ED
patients.
Conclusions
Supplementation with 10 mg/day of folic acid for six
months in patients with EDs (RAN and EDNOS) and
low folate intake produced an improvement in folate
status, as well as, significant reduction in Hcy levels
and significant and favourable changes in most test
scores for cognitive and depressive status. Supplemen-
tation was safe and vitamin B12 levels were not
affected.
Further studies with larger sample sizes are needed
to expand and support these results.
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